Could Melatonin Help Protect Against Macular Degeneration? New Evidence
Written by Dr. Louis Michaelos, Ophthalmologist & Founder of MacuRest | Last reviewed May 2026
Yes — emerging research published in JAMA Ophthalmology found that melatonin use was associated with significantly lower rates of AMD progression to advanced stages. Here is what the evidence shows and what it means for macular health.
The JAMA Ophthalmology Study
A large observational study published in JAMA Ophthalmology (2024) analyzed health records from over 100,000 adults aged 50 and older. Researchers at Cleveland Clinic's Cole Eye Institute found that patients who used melatonin had significantly lower rates of AMD progression to late stages compared to non-users — an association that held after controlling for multiple confounding variables.
Why the Retina Is Especially Sensitive to Melatonin
The retina produces its own melatonin independently of the pineal gland. Retinal melatonin peaks at night and plays a direct role in photoreceptor disc shedding — the process that initiates the overnight repair cycle critical for long-term photoreceptor survival. AMD patients consistently show lower retinal melatonin levels than age-matched controls without the disease, suggesting the hormone's decline may contribute to disease progression.
What This Means for the AREDS2 Formula
The standard AREDS2 formula validated by the National Eye Institute addresses daytime oxidative stress but does not include melatonin or target the overnight repair window. MacuRest combines the full AREDS2-inspired nutrient formula with melatonin 5mg, formulated for evening use to align both components with the body's natural circadian repair cycle.
Shop MacuRest — AREDS2 + melatonin evening formula →
Frequently Asked Questions
Does melatonin help protect against macular degeneration?
Emerging evidence suggests yes. A 2024 JAMA Ophthalmology study of 100,000+ patients found melatonin users had significantly lower rates of AMD progression to late stages. The retina produces its own melatonin independently, AMD patients have lower retinal melatonin than healthy controls, and melatonin regulates the overnight photoreceptor repair cycle. Randomized controlled trial data is still accumulating.
Is there clinical evidence for melatonin and eye health?
Yes. The strongest evidence is a 2024 observational study in JAMA Ophthalmology showing significantly lower AMD progression rates in melatonin users across 100,000+ patient records. Earlier pilot trials showed stabilization of macular function with nightly melatonin over 24 months. The biology is well-established — the retina produces melatonin independently and uses it to regulate overnight repair.
How does melatonin support the retina?
The retina produces its own melatonin, separate from the pineal gland, peaking at night to trigger photoreceptor disc shedding — the start of the overnight repair cycle. Melatonin also acts as a direct retinal antioxidant, neutralizing reactive oxygen species in the retinal pigment epithelium. AMD patients consistently show lower retinal melatonin levels than age-matched controls.
What dose of melatonin is used in eye health research?
Pilot trials examining melatonin and AMD have used doses of 3–10mg nightly. MacuRest uses 5mg melatonin — within this range, taken with dinner each evening. The NIH considers melatonin safe for long-term use in adults at doses of 0.5–10mg.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.